Advising people all over the world on health issues and enabling them to lead healthier lives was the driving force behind our company founder - this is how the Swabian success story began.
Our biofactors set standards in over 35 countries. In every country where we do business we want to meet the highest expectations of its market. Therefore we have a specific product portfolio in each country.
An international expert panel published recommendations for diagnosis and management of diabetic neuropathy. Wörwag Pharma provides information on the current consensus recommendations for health care professionals.
Böblingen, February 17th, 2022 – The Boeblingen-based family-owned company Wörwag Pharma invested in several strategic milestones in 2021 and successfully closed the year with a year-on-year increase in sales to 269.9 million euros. The signs continue to focus on investment and growth.
In order to support science and research, Wörwag Pharma has awarded the 10th Fritz Wörwag Research Prize this year. The prize rewards new research findings in the field of biofactors – this year on “Biofactors in diabetes and its comorbidities“.
